Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Inside CARB-X: can this new model for research fix a broken antibiotics market?

Resistance to antibiotics is rising but the business model for developing new antibiotic drugs is broken. Could CARB-X, the world’s largest public-private partnership devoted to antibacterial research and development, be the answer? Patrick Kingsland finds out more from CARB-X executive director Kevin Outterson.

Download our 2018 Technology, Media & Telecoms Predictions worth over $5,000 for free


Go Top